Our Board

Sickle Cell Prodigy is guided by a dedicated group of board members and advisors who are deeply committed to our mission: helping people with sickle cell disease navigate the full journey of transformative therapy—from treatment options to life after therapy—with clarity, confidence, and community.

Together, they provide strategic oversight and ensure that Sickle Cell Prodigy remains accountable to the community it serves—today and as the treatment landscape continues to evolve.

Board of Directors

Our Board of Directors guide our vision, safeguard our independence, and strengthen our commitment to care beyond treatment. We are grateful for their leadership and dedication to building a future where survivorship is fully supported.

ChatGPT Image Jan 27, 2026 at 09_09_27 PM.png

Kay-Diene Robinson, MPH

Board Chair, Programs & Partnerships

Kay-Diene Robinson, MPH, CHW, is a seasoned rare disease professional, a former sickle cell hemoglobin-SS patient, and a Diversity and inclusion expert. Her journey as a patient advocacy leader began in 2013 and has been marked by highly successful collaborations with thought leaders, healthcare professionals, policymakers, and pharmaceutical collaborations.

Dr. Melissa Creary, MPH

Board Member, Equity & Community Voice

Melissa Creary, PhD, MPH is an Associate Professor of Health Management and Policy at The University Of Michigan School of Public Health. With over 20 years of experience, she has dedicated her career to the sickle cell and bleeding disorder communities in roles as a scientist, policy maker, and researcher. A globally speaker, she has addressed justice, racism, anti-racism in health, and biomedicine in over 10 countries.

ChatGPT Image Jan 27, 2026 at 01_03_32 AM.png

Ashley Buscetta, MSN, FNP-BC

Board Member, Clinical Research

Ashley Buscetta, MSN, FNP-BC, CWOCN is a Clinical Trials Program Coordinator in the Office of the Associate Director of the Healthcare Delivery Research Program. A family nurse practitioner and certified wound, ostomy, continence nurse (CWOCN) by training, Ashley serves as the Project Scientist in the NCI Community Oncology Research Program (NCORP).

Screenshot 2026-02-10 at 11.16.25 AM.png

Dr. Matthew Porteus

Board Member, Clinical Research

Dr. Matthew Porteus is an Associate Professor of Pediatrics at Stanford School of Medicine in the Divisions of Hematology/Oncology and Human Gene Therapy. His research focuses on developing gene-editing therapies for genetic diseases using homologous recombination, and he was the first to demonstrate that engineered nucleases can precisely modify human cells. He earned his undergraduate degree from Harvard University and completed his M.D. and Ph.D. at Stanford.

Shirlanna Station, CSM

Board Member, Data Integrity

Shirlanna Station, CSM is a results-driven clinical research professional with expertise in oncology and hematology trial operations. She brings strong analytical skills and a deep understanding of clinical research protocols, with experience managing deliverables across multiple stages of the research lifecycle. She specializes in data reconciliation and data integrity using SaaS-based systems, ensuring regulatory compliance in alignment with ICH-GCP and IRB standards. Shirlanna is committed to strengthening regulatory rigor.

Dr. Elizabeth Krieger

Board Member, Clinical Research

Dr. Krieger is a pediatric hematologist-oncologist specializing in bone marrow transplant and cellular therapies at Virginia Commonwealth University. She trained with leading experts in the field of bone marrow transplant and cellular therapies for rare conditions including Fanconi's anemia, metabolic disorders, immunodeficiency and cellular therapies at the University of Minnesota. Krieger is an active member of the American Society of Transplantation and Cellular Therapies and the National Marrow Donor Program.

ChatGPT Image Feb 9, 2026 at 12_23_21 PM.png

Jade Parker-Dinkins, BSN, RN

Board Member, Development & Partnerships

Jade Parker-Dinkins is a sickle cell disease patient, nurse, and researcher dedicated to advancing patient-centered solutions at the intersection of healthcare delivery, quality improvement, and lived experience. With more than 10 years of clinical nursing experience and over 20 years of advocacy, she specializes in identifying operational gaps, designing culturally responsive care strategies, and implementing evidence-informed improvements.

ChatGPT Image Feb 6, 2026 at 04_26_24 PM.png

Adebola Enikanolaiye, PhD

Board Member, Programs & Impact

Adebola Enikanolaiye, PhD is a scientist with expertise in drug discovery, in vivo biology, and pharmacology, with a strong background in genetic and biomedical research. She has contributed to scientific research in rare diseases and model systems that inform therapeutic discovery and pre-clinical efficacy. Her work has involved advancing understanding of disease mechanisms and supporting translational science efforts to improve health outcomes.

Maite Rodriguez-Caraballo, MSW

Board Member, Caregiver Support

Maite Rodriguez is a children’s book author, social worker, and educator with a background in special education. An immigrant from the Dominican Republic, she draws on her personal and professional experiences to create heartfelt stories that inspire, empower, and reflect the diverse journeys of children and families. Her debut book, Just Like the Moon, was inspired by her daughter, Alessia’s courageous battle with sickle cell disease and transplant.

Taylor John

Board Member, Community Voice

Taylor John is among the first individuals with Sickle Cell Beta Thalassemia to undergo CRISPR gene-editing therapy, bringing a powerful lived perspective to conversations around genetics, biotechnology, and patient-centered care. Drawing from her experience navigating chronic illness and transformative treatment, she is a passionate advocate for health equity and access. He has spoken at national and community forums, including the National Society of Genetic Counselors Annual Conference.

Board Advisors

Our Board Advisors serve in a non-governing, non-voting capacity and play a critical role in strengthening Sickle Cell Prodigy’s impact through strategic insight, subject-matter expertise, and informed guidance.